Telemedical Interventional Management in Heart Failure II - TIM-HF2

Charité Campus Charité Mitte0 个研究点目标入组 1,571 人开始时间: 2016年4月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. chronic heart failure New York Heart Association (NYHA) class II or III; 2. echocardiographically determined left ventricular ejection fraction (LVEF) =45% or >45% + minimum 1 diuretic in permanent medicinal therapy;
•3. hospitalization due to decompensated HF within the last 12months before randomization; 4. informed consent; 5. depression score (PHQ-9 <10)

•Hospitalization within the last 7 days before randomization; Implanted cardiac assist system
•Acute coronary syndrome within the last 7 days before randomization; High urgent listed for heart transplantation (HTx); Planned revascularization, Transcatheter Aortic Valve Implantation (TAVI), MitraClip and/or Cardiac Resynchronization Therapy (CRT)-implantation within the last 3 months before randomization
•Revascularization and/or CRT-implantation within 28 days before randomization;
•Known alcohol or drug abuse; Terminal renal insufficiency with hemodialysis;
•Impairment or unwillingness to use the telemonitoring equipment (e.g. dementia, impaired self-determination, lacking ability to communicate); Existence of any disease reducing life expectancy to less than 1 year; Age <18 years; Pregnancy; Participation in other treatment studies or remote patient management programmes (register studies possible)

发起方

Charité Campus Charité Mitte